| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Pharmacological management of type 2 diabetes mellitus in children and adolescents: A systematic review and network meta-analysis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Charles A Gagnon, Katherine Buchanan, Jill M Deaver, Jessica A Schmitt, Ian M Lahart, Sahana Shetty, Ambika P Ashraf and Joseph M Pappachan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Joseph M Pappachan, Academic Editor, FRCP, MD, MRCP, Professor, Senior Researcher, Faculty of Science, Manchester Metropolitan University, All Saints Building, Manchester M15 6BH, Greater Manchester, United Kingdom. drpappachan@yahoo.co.in |
| Key Words |
Type 2 diabetes mellitus; Pharmacotherapy; Children; Adolescents; Obesity; Diabesity; Glycemic control |
| Core Tip |
Although the prevalence of obesity and type 2 diabetes are increasing among children, there is only limited evidence on pharmacotherapeutic interventions to address the issue. Twelve studies including 1658 participants (follow-up: 12-52 weeks) in this meta-analysis revealed that dulaglutide, dapagliflozin, liraglutide, empagliflozin, exenatide, and linagliptin treatment resulted in mean glycated hemoglobin reductions of -1.20%, -0.94%, -0.91%, -0.87%, -0.59% and -0.45% respectively, while other drugs had little/no effect. No drug treatment conferred significant changes in body weight (except liraglutide), body mass index, and lipids. Except for mild hypoglycemia with liraglutide and minor adverse events with dulaglutide use, pharmacotherapy was generally safe. |
| Publish Date |
2025-07-15 08:26 |
| Citation |
<p>Gagnon CA, Buchanan K, Deaver JM, Schmitt JA, Lahart IM, Shetty S, Ashraf AP, Pappachan JM. Pharmacological management of type 2 diabetes mellitus in children and adolescents: A systematic review and network meta-analysis. <i>World J Diabetes</i> 2025; 16(7): 106890</p> |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i7/106890.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i7.106890 |
